Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome

Biomarkers

Volumn 16, Issue 8, 2011, Pages 657-662

  Shang, Fu Jun ^a   Wang, Jie Pin ^a   Liu, Xiong Tao ^a   Zheng, Qiang Sun ^a   Xue, Yu Sheng ^a   Wang, Bin ^a   Zhao, Lian You ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Adipokines; Biomarker; Cardiometabolic syndrome; Coronary atherosclerosis index

Indexed keywords

ADIPOCYTOKINE; OMENTIN 1; UNCLASSIFIED DRUG;

ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ATHEROSCLEROSIS INDEX; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PATHOGENESIS; PREDICTION; PREDICTIVE VALIDITY; PROTEIN BLOOD LEVEL; RATING SCALE; SENSITIVITY AND SPECIFICITY;

CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CYTOKINES; GPI-LINKED PROTEINS; HUMANS; LECTINS; METABOLIC SYNDROME X;

EID: 81855211107     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2011.622789     Document Type: Article

References (20)

1. Deng Y, Scherer PE. (2010). Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci 1212:E1-E19.
2. Eckel RH, Grundy SM, Zimmet PZ. (2005). Te metabolic syndrome. Lancet 365:1415-1428.
3. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F; American Heart Association; National Heart, Lung, and Blood Institute. (2005). Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientifc Statement. Circulation 112:2735-2752. (Pubitemid 41532612)
4. Hunt KJ, Resendez RG, Williams K, Hafner SM, Stern MP; San Antonio Heart Study. (2004). National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110:1251-1257. (Pubitemid 39202341)
5. Joint Committee for Developing Chinese guidelines on Prevention and Treatment of Dyslipidemia in Adults. (2007). Zhonghua Xin Xue Guan Bing Za Zhi 35:390-419.
6. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. (2002). Te metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709-2716. (Pubitemid 35403784)
7. Liu R, Wang X, Bu P. (2011). Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract [Epub ahead of print].
8. Mitsutake R, Miura S, Kawamura A, Saku K. (2009). Are metabolic factors associated with coronary artery stenosis on MDCT? Circ J 73:132-138.
9. Moreno-Navarrete JM, Catalán V, Ortega F, Gómez-Ambrosi J, Ricart W, Frühbeck G, Fernández-Real JM. (2010). Circulating omentin concentration increases after weight loss. Nutr Metab (Lond) 7:27.
10. Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernández-Real JM. (2011). Circulating Omentin as a Novel Biomarker of Endothelial Dysfunction. Obesity (Silver Spring)
11. Ouchi N, Parker JL, Lugus JJ, Walsh K. (2011). Adipokines in infammation and metabolic disease. Nat Rev Immunol 11:85-97.
12. Pan HY, Guo L, Li Q. (2010). Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 88:29-33.
13. Rein P, Saely CH, Beer S, Vonbank A, Drexel H. (2010). Roles of the metabolic syndrome, HDL cholesterol, and coronary atherosclerosis in subclinical infammation. Diabetes Care 33:1853-1855.
14. Schäfer A, Neumeier M, Herfarth H, Fürst A, Schölmerich J, Büchler C. (2005). Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 1732:96-102. (Pubitemid 43267310)
15. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, Fried SK, Gong DW, Shuldiner AR, Pollin TI, McLenithan JC. (2007). Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56:1655-1661. (Pubitemid 46842600)
16. Tan BK, Pua S, Syed F, Lewandowski KC, O'Hare JP, Randeva HS. (2008). Decreased plasma omentin-1 levels in Type 1 diabetes mellitus. Diabet Med 25:1254-1255.
17. Tatami R, Mabuchi H, Ueda K, Ueda R, Haba T, Kametani T, Ito S, Koizumi J, Ohta M, Miyamoto S, Nakayama A, Kanaya H, Oiwake H, Genda A, Takeda R. (1981). Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation 64:1174-1184. (Pubitemid 12236146)
18. Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y (2010). Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun 393:668-672.
19. Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y (2011). Biochem Biophys Res Commun 408:339-343.
20. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC, Gong DW. (2006). Identifcation of omentin as a novel depot-specifc adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 290:E1253-E1261. (Pubitemid 43847911)